BR0014269A - Lactam compounds, their pharmaceutically acceptable salts and prodrugs, pharmaceutical composition, method of treating neurological disorders associated with the production of "beta" -amyloid, method of inhibiting "alpha" -secretase activity and uses of the compounds - Google Patents

Lactam compounds, their pharmaceutically acceptable salts and prodrugs, pharmaceutical composition, method of treating neurological disorders associated with the production of "beta" -amyloid, method of inhibiting "alpha" -secretase activity and uses of the compounds

Info

Publication number
BR0014269A
BR0014269A BR0014269-7A BR0014269A BR0014269A BR 0014269 A BR0014269 A BR 0014269A BR 0014269 A BR0014269 A BR 0014269A BR 0014269 A BR0014269 A BR 0014269A
Authority
BR
Brazil
Prior art keywords
compounds
amyloid
production
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Application number
BR0014269-7A
Other languages
Portuguese (pt)
Inventor
Richard Eric Olson
Hong Liu
Lorin Andrew Thompson Iii
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of BR0014269A publication Critical patent/BR0014269A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS DE LACTAMAS, SEUS SAIS E PRó-DROGAS FARMACEUTICAMENTE ACEITáVEIS, COMPOSIçãO FARMACêUTICA, MéTODO DE TRATAMENTO DE DISFUNçõES NEUROLóGICAS ASSOCIADAS COM A PRODUçãO DE <225>-AMILóIDE, MéTODO DE INIBIçãO DA ATIVIDADE DA <sym>-SECRETASE E USOS DOS COMPOSTOS". A presente invenção refere-se a lactamas inovadoras que possuem a fórmula (I), suas composições farmacêuticas e seus métodos de utilização. Esses compostos inovadores inibem o processamento de proteína precursora de amilóide e, mais especificamente, inibem a produção de peptídeo-A<225>, de forma a agirem para evitar a formação de depósitos neurológicos de proteína de amilóide. Mais especificamente, a presente invenção refere-se ao tratamento de disfunções neurológicas relativas à produção de <255>-amilóide, tais como o mal de Alzheimer e a Síndrome de Down."LACTAMS COMPOUNDS, THEIR SALTS AND prodrugs pharmaceutically acceptable, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT disorders neurological ASSOCIATED WITH PRODUCTION <225> amyloid, method of inhibiting ACTIVITY <sym> secretase AND USES OF COMPOUNDS" . The present invention relates to innovative lactams that have the formula (I), their pharmaceutical compositions and their methods of use. These innovative compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A-peptide <225>, in order to act to prevent the formation of neurological deposits of amyloid protein. More specifically, the present invention relates to the treatment of neurological disorders related to the production of? -Amyloid, such as Alzheimer's disease and Down's syndrome.

BR0014269-7A 1999-09-13 2000-09-13 Lactam compounds, their pharmaceutically acceptable salts and prodrugs, pharmaceutical composition, method of treating neurological disorders associated with the production of "beta" -amyloid, method of inhibiting "alpha" -secretase activity and uses of the compounds BR0014269A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15351199P 1999-09-13 1999-09-13
US22438800P 2000-08-09 2000-08-09
PCT/US2000/024967 WO2001019797A2 (en) 1999-09-13 2000-09-13 HYDROXYALKANOYL AMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF Aβ PROTEIN PRODUCTION

Publications (1)

Publication Number Publication Date
BR0014269A true BR0014269A (en) 2002-07-02

Family

ID=26850619

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014269-7A BR0014269A (en) 1999-09-13 2000-09-13 Lactam compounds, their pharmaceutically acceptable salts and prodrugs, pharmaceutical composition, method of treating neurological disorders associated with the production of "beta" -amyloid, method of inhibiting "alpha" -secretase activity and uses of the compounds

Country Status (9)

Country Link
EP (1) EP1212306A2 (en)
JP (1) JP2003509411A (en)
CN (1) CN1399634A (en)
AU (1) AU783914B2 (en)
BR (1) BR0014269A (en)
CA (1) CA2377221A1 (en)
IL (1) IL147774A0 (en)
MX (1) MXPA02001813A (en)
WO (1) WO2001019797A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
DE60124080T2 (en) 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco COMPOUNDS AND METHOD FOR THE TREATMENT OF ALZHEIMER'S DISEASE
CA2403550A1 (en) * 2000-04-03 2001-10-11 Hong Liu Cyclic lactams as inhibitors of a-.beta. protein production
US6632812B2 (en) 2000-04-11 2003-10-14 Dupont Pharmaceuticals Company Substituted lactams as inhibitors of Aβ protein production
WO2001087354A2 (en) 2000-05-17 2001-11-22 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
GB0012671D0 (en) 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
EP1666452A2 (en) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
PE20020276A1 (en) 2000-06-30 2002-04-06 Elan Pharm Inc SUBSTITUTE AMINE COMPOUNDS AS ß-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER
CN100562516C (en) * 2001-12-27 2009-11-25 第一制药株式会社 Amyloid-beta produces and the excretory inhibitor
US6974829B2 (en) 2002-05-07 2005-12-13 Elan Pharmaceuticals, Inc. Succinoyl aminopyrazoles and related compounds
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
EP1633350B1 (en) 2003-06-05 2012-10-03 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2008141081A1 (en) 2007-05-10 2008-11-20 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP2489656A1 (en) 2007-12-21 2012-08-22 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
ATE296797T1 (en) * 1996-11-22 2005-06-15 Elan Pharm Inc N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS THEREFOR, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE OR SYNTHESIS
PL196641B1 (en) 1996-12-23 2008-01-31 Elan Pharm Inc Cycloalkylic, lactamic, lactonic and affinite compounds, pharmaceutic agents containing them and methods of inhibiting ß-amyloid peptide release and/or synthesis thereof employing such compounds
KR20010033408A (en) * 1997-12-22 2001-04-25 진 엠. 듀발 Polycyclic α-Amino-ε-Caprolactams and Related Compounds
AU4710499A (en) 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use ofsuch compounds
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
EP1313426A2 (en) 1998-12-24 2003-05-28 Bristol-Myers Squibb Pharma Company Succinoylamino benzodiazepines as inhibitors of a-beta protein production

Also Published As

Publication number Publication date
IL147774A0 (en) 2002-08-14
JP2003509411A (en) 2003-03-11
AU7479700A (en) 2001-04-17
CA2377221A1 (en) 2001-03-22
AU783914B2 (en) 2005-12-22
MXPA02001813A (en) 2004-03-19
WO2001019797A3 (en) 2002-04-11
EP1212306A2 (en) 2002-06-12
WO2001019797A2 (en) 2001-03-22
CN1399634A (en) 2003-02-26

Similar Documents

Publication Publication Date Title
BR9917082A (en) Compounds that inhibit the production of &#34;beta&#34; proteins, a method of treating neurological disorders associated with the production of &#34;beta&#34; -amyloid, pharmaceutical composition and, method of inhibiting y-secretase activity
BR0106717A (en) Compounds, pharmaceutical composition and uses of innovative lactam compounds
BR0014269A (en) Lactam compounds, their pharmaceutically acceptable salts and prodrugs, pharmaceutical composition, method of treating neurological disorders associated with the production of &#34;beta&#34; -amyloid, method of inhibiting &#34;alpha&#34; -secretase activity and uses of the compounds
BR0107532A (en) Compound, use of compound, method for treating neurological dysfunctions associated with b-amyloid production, method of inhibiting y-secretase activity and pharmaceutical composition
BR9912969A (en) Compound, pharmaceutical composition, method for the treatment of neurological disorders associated with the production of b-amyloid, method for the treatment of alzheimer&#39;s disease associated with the production of b-amyloid, method for the treatment of neurological disorders associated with the production of b-amyloid and method to inhibit y-secretase activity
DE69429527D1 (en) INHIBITORS OF BETA AMYLOID PROTEIN PRODUCTION
BR0110051A (en) Compound, Compound Use, Pharmaceutical Composition and Method of Treatment of Alzheimer&#39;s Disease
BRPI0011867B8 (en) pharmaceutical preparation of levodopa/carbidopa/entacapone and process for its preparation
BR0116201A (en) Compound, process for the preparation of a compound, pharmaceutical composition comprising the compound, use of the compound, process for the treatment and prophylaxis of disorders and for the treatment of obesity.
BR9709959A (en) Tricyclic derivatives of substituted phenylamino for the treatment of hyperproliferative diseases
BR0108610A (en) Azapolycyclic compounds condensed with aryl
ECSP055719A (en) TIAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
BR9807876A (en) Heterocyclic compounds and their use for inhibition of beta-amyloid peptide
BR0012590A (en) Compound, process for its preparation, pharmaceutical formulation, use of a compound, and, methods for treatment or prophylaxis of pain or discomfort, and for treatment or prophylaxis of neuropathic or central pain
MX9307062A (en) QUINUCLIDINE DERIVATIVE FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND THE CENTRAL NERVOUS SYSTEM.
DE69731610D1 (en) ORAL ADMINISTRATION OF EFFECTIVE AMOUNTS OF HYALURONIC ACID
ATE253918T1 (en) USE OF HYMENIALDISINE AND ITS DERIVATIVES FOR THE PRODUCTION OF THERAPEUTIC AGENTS
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
BR9900856A (en) 3,6-ketal and enol-ether macrolide antibiotics
CY1111615T1 (en) ARYLVINYLACACYCALCOLANES AND METHODS OF PREPARATION AND THEIR USE.
BR9812577A (en) Compound, process for preparing the same, pharmaceutical composition, and process for treating bacterial infections
BR0312780A (en) Substituted thiophene carboxamide compounds for the treatment of inflammation
BRPI0409151A (en) use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
ATE285773T1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
BR0116263A (en) Dihydroindole and Tetrahydroquinoline Derivatives

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]